Feasibility study of a combi-pv panel for greenhouse energy supply and water recovery by nightly radiation towards the sky

In southern European areas, characterized by high irradiation, the use of water for both evaporative cooling systems and hydroponic fertigation, represents a serious drawback for crop cultivation under cover. Water recovery systems seem to be an attractive solution, especially when they are integrated in the greenhouse construction. In this research, a feasibility study of applying a water recovery system driven by a combi-PV panel, in a semi-closed greenhouse was carried out. The prototype combi-PV panel was made by coupling an amorphous silicon panel with a sump stacked on the rear PV panel surface and filled with saline water. The system is driven by a cold-heat sink which is the PV panel itself. During night, the combi-PV panel exploits the radiative cooling of a ‘gray’ surface towards clear sky, chilling the water in the sump. In opposition, during day-time, the water in the sump is heated at a temperature higher than the environment. Thus, the water vapour will be condensing on the rear panel surface during night, being the warm air circulation facilitated by bouyancy effect. The evaluation of the system is in progress in order to assess the real amount of energy irradiated and consequently the water-drips to be collected on a proper surface inside the sump. The condensed water can be mixed with saline water to reduce the salinity and be used for fertigation

Clinical, magnetic resonance imaging, and histopathologic features of a hypoglossal malignant peripheral nerve sheath tumor in a maltese dog

Malignant tumours arising from peripheral nerves or displaying differentiation along the lines of the various elements of the nerve sheath are collectively referred to as MPNSTs. Histologically, in human MPNST, the malignant nature of these tumours is associated with an infiltrative and cellular proliferation of atypical, mitotically active spindle cells. Their predilection for sites varies with the species. In dogs the most common site for MPNST is the nerve roots or nerves of the brachial plexus, while the cranial nerve more frequently involved is the trigeminal nerve. In humans, hypoglossal peripheral nerve sheath tumours are rare, only few cases are described in literature; and the malignant forms are even exceptional. Fifty per cent of cases displayed both an intra- and extracrania component, and are referred as dumbbell-shaped tumours. To our knowledge this is the first case report an hypoglossal MPNST in a dog. In our case the tumour was dumbbell-shaped, with both intra-and extracranial components and associated with characteristic clinical signs of hypoglossal tumour. The malignant histological appearance of the lesion occurred without infiltrative growth

Quantification and characterization of the environmental impact of sea bream and sea bass production in Italy

While the production of fish from aquaculture has grown steadily over the years worldwide, some environmental concerns have emerged. In this study, the environmental impacts and main hotspots of a typical Italian sea bass and sea bream offshore farm were analysed. The Life Cycle Assessment (LCA) methodology was applied with a “cradle to farm gate” perspective and 1 ton of fish at harvest size as the functional unit. The results confirm that feed is the main hotspot and contributes across impact categories always at least 60%, with the exception of marine eutrophication driven instead by nutrient emissions. In some impact categories, infrastructure and farm operations also have a relevant impact (about 30%). The impacts of this case study are slightly lower than those found in the literature, and this is mainly due to prior attention of the company to feed formulation. An alternative scenario was also explored, by reducing the amount of uningested feed, showing a reduction in the Global Warming Potential by 6% and in marine eutrophication by up to 10%. The application and evaluation of new technologies (e.g., automated feed dispenser, use of alternative cage materials) could be explored in future research

Clinical, magnetic resonance imaging, and histopathologic features of hypothalamic neuronal hamartoma in a young vizsla

Hypothalamic hamartomas (HH) are rare, tumor-like malformations thatoccurduring fetal development and are present at birth. They differ from neoplasms since they are not autonomous and they grow in proportion to normal brain growth, and consequently their relative size to the rest of the brain is the same for the lifetime of the patient. Hamartomas are non-progressive lesions and do not expand, spread or metastasize to other locations. In canine nervous system, vascular, neuronal and peripheral nerve fibers hamartomas have been described; to our knowledge, this is the first report describing the MRI features of a hypothalamic neuronal hamartoma in a dog

Fishmeal replacement with hermetia illucens meal in aquafeeds: Effects on zebrafish growth performances, intestinal morphometry, and enzymology

Fishmeal (FM) is still the most important protein source in aquafeeds. However, due to the reduction of wild fish stocks used for FM production, its manufacturing it is now unsustainable. Insect meal represents a valid alternative to FM, due to the low carbon footprint of its production and its high nutritional value. The aim of this study was to investigate the potentials of replacing FM with black soldier fly (Hermetia illucens) meal (HIM) in aquafeeds, using zebrafish as the animal model. Four diets were formulated with increasing HIM/FM replacement rate (the control diet contained 20% FM). Mortality rates, growth performances, and feed consumptions were measured, and fish intestine samples were collected for histological and enzymatic analysis. After 49 days, all groups almost tripled their initial body weight (cumulative body weight gain ranged between 143.9 and 155.2 mg), and no statistically significant differences among treatments were observed in relation to growth performances and histological traits. Contrarily, trypsin, alkaline phosphatases, and alpha amylase–glucoamylase activities were significantly reduced when the FM replacement rate was increased. In conclusion, HIM may represent an alternative to FM, since no adverse effects were observed when it was included up to 20% in the zebrafish diet, even when replacing 100% of the FM

Effects of amantadine on circulating neurotransmitters in healthy subjects

Considering that glutamatergic axons innervate the C1(Ad) medullary nuclei, which are responsible for the excitation of the peripheral adrenal glands, we decided to investigate catecholamines (noradrenaline, adrenaline and dopamine) plus indolamines (plasma serotonin and platelet serotonin) at the blood level, before and after a small oral dose of amantadine, a selective NMDA antagonist. We found that the drug provoked a selective enhancement of noradrenaline plus a minimization of adrenaline, dopamine, plasma serotonin and platelet serotonin circulating levels. Significant enhancement of diastolic blood pressure plus reduction of systolic blood pressure and heart rate paralleled the circulating parameter changes. The above findings allow us to postulate that the drug was able to enhance the peripheral neural sympathetic activity. Minimization of both adrenal sympathetic and parasympathetic activities was also registered after the amantadine challenge. The above findings supported the postulation that this drug should be a powerful therapeutic tool for treating diseases affected by adrenal sympathetic hyperactivity

Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease

<p>Abstract</p> <p>Background</p> <p>Donepezil 23 mg/d, recently approved in the United States for treatment of moderate to severe Alzheimer's disease (AD), was developed to address the need for an additional treatment option for patients with advanced AD. This report, based on a pivotal phase 3 study, presents a detailed analysis of the safety and tolerability of increasing donepezil to 23 mg/d compared with continuing 10 mg/d.</p> <p>Method</p> <p>Safety analyses comprised examination of the incidence, severity, and timing of treatment-emergent adverse events (AEs) and their relationship to treatment initiation; changes in weight, electrocardiogram, vital signs, and laboratory parameters; and the incidence of premature study discontinuation. The analysis population (n = 1434) included all randomized patients who took at least 1 dose of study drug and had a postbaseline safety assessment. To further examine the effect of transition from a lower to a higher donepezil dose, a pooled analysis of safety data from 2 phase 3 trials of donepezil 5 mg/d and 10 mg/d was also performed.</p> <p>Results</p> <p>The safety population comprised 1434 patients: donepezil 23 mg/d (n = 963); donepezil 10 mg/d (n = 471); completion rates were 71.1% and 84.7%, respectively. The most common AEs were nausea, vomiting, and diarrhea (donepezil 23 mg/d: 11.8%, 9.2%, 8.3%; donepezil 10 mg/d: 3.4%, 2.5%, 5.3%, respectively). AEs that contributed most to early discontinuations were vomiting (2.9% of patients in the 23 mg/d group and 0.4% in the 10 mg/d group), nausea (1.9% and 0.4%), diarrhea (1.7% and 0.4%), and dizziness (1.1% and 0.0%). The percentages of patients with AEs in the 23 mg/d group, as well as the timing, type, and severity of these AEs, were similar to those seen in previous donepezil trials with titration from 5 to 10 mg/d. Serious AEs were uncommon (23 mg/d, 8.3%; 10 mg/d, 9.6%).</p> <p>Discussion</p> <p>The 23 mg/d dose of donepezil was associated with typical cholinergic AEs, particularly gastrointestinal-related AEs, similar to those observed in studies with a dose increase from 5 to 10 mg/d.</p> <p>Conclusion</p> <p>The good safety and predictable tolerability profile for donepezil 23 mg/d supports its favorable risk/benefit ratio in patients with moderate to severe AD.</p> <p>Trial Registration</p> <p><a href="http://www.clinicaltrials.gov/ct2/show/NCT00478205">NCT00478205</a></p

Ataluren delays loss of ambulation and respiratory decline in nonsense mutation Duchenne muscular dystrophy patients

Aim: We investigated the effect of ataluren plus standard of care (SoC) on age at loss of ambulation (LoA) and respiratory decline in patients with nonsense mutation Duchenne muscular dystrophy (nmDMD) versus patients with DMD on SoC alone. / Patients & methods: Study 019 was a long-term Phase III study of ataluren safety in nmDMD patients with a history of ataluren exposure. Propensity score matching identified Study 019 and CINRG DNHS patients similar in disease progression predictors. / Results & conclusion: Ataluren plus SoC was associated with a 2.2-year delay in age at LoA (p = 0.0006), and a 3.0-year delay in decline of predicted forced vital capacity to <60% in nonambulatory patients (p = 0.0004), versus SoC. Ataluren plus SoC delays disease progression and benefits ambulatory and nonambulatory patients with nmDMD. / ClinicalTrials.gov: NCT01557400

Simvastatin Prevents Dopaminergic Neurodegeneration in Experimental Parkinsonian Models: The Association with Anti-Inflammatory Responses

Background: In addition to their original applications to lowering cholesterol, statins display multiple neuroprotective effects. N-methyl-D-aspartate (NMDA) receptors interact closely with the dopaminergic system and are strongly implicated in therapeutic paradigms of Parkinson’s disease (PD). This study aims to investigate how simvastatin impacts on experimental parkinsonian models via regulating NMDA receptors. Methodology/Principal Findings: Regional changes in NMDA receptors in the rat brain and anxiolytic-like activity were examined after unilateral medial forebrain bundle lesion by 6-hydroxydopamine via a 3-week administration of simvastatin. NMDA receptor alterations in the post-mortem rat brain were detected by [3H]MK-801(Dizocilpine) binding autoradiography. 6-hydroxydopamine treated PC12 was applied to investigate the neuroprotection of simvastatin, the association with NMDA receptors, and the anti-inflammation. 6-hydroxydopamine induced anxiety and the downregulation of NMDA receptors in the hippocampus, CA1(Cornu Ammonis 1 Area), amygdala and caudate putamen was observed in 6- OHDA(6-hydroxydopamine) lesioned rats whereas simvastatin significantly ameliorated the anxiety-like activity and restored the expression of NMDA receptors in examined brain regions. Significant positive correlations were identified between anxiolytic-like activity and the restoration of expression of NMDA receptors in the hippocampus, amygdala and CA1 following simvastatin administration. Simvastatin exerted neuroprotection in 6-hydroxydopamine-lesioned rat brain and 6- hydroxydopamine treated PC12, partially by regulating NMDA receptors, MMP9 (matrix metalloproteinase-9), and TNF-a (tumour necrosis factor-alpha). Conclusions/Significance: Our results provide strong evidence that NMDA receptor modulation after simvastatin treatment could partially explain its anxiolytic-like activity and anti-inflammatory mechanisms in experimental parkinsonian models. These findings contribute to a better understanding of the critical roles of simvastatin in treating PD via NMDA receptors